Editorial: Medication safety in COVID-19 management, Volume II

Editorial on the Research Topic Medication safety in COVID-19 management, Volume IIThe COVID-19 pandemic had disrupted the global healthcare ecosystem.To battle this, numerous treatment methods were attempted (WHO, 2022; EMA, 2023; US FDA, 2023).Although a few new medicines were introduced, a majority of the medicines to treat COVID-19 are repurposed ones.Despite lacking adequate safety data, certain medicines were granted emergency use authorizations.Likewise, several COVID-19 vaccines have been developed and widely used globally (CDC, 2023).As the severity of the COVID-19 pandemic has now reduced globally, optimizing medication management in COVID-19 is crucial and it is necessary to discontinue the use of ineffective medicines (Abdool Karim et al., 2022).It is important to conduct a large-scale evaluation of the safety profile of COVID-19 medicines, as well as vaccines (Chiu et al., 2022).This issue has been dedicated to the safety aspects of pharmacotherapy for COVID-19.Merino et al. aimed to investigate the potential link between the development of transient global amnesia following the administration of COVID-19 vaccines.The World Health

Abstract licence: CC BY

4 more references, whose wording the paper’s licence keeps private.

A person counts once a day per paper. We keep no cookie and no address: a reader is a hash that changes every day. Any month under five reads shows no number.